Cortice Biosciences Announces Results From Studies

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cortice Biosciences Announces Results From Studies Evaluating Pipeline Candidates TPI 287 and CRT 001 in Preclinical Models of Tauopathies and Alzheimer's Disease

— TPI 287 improves cognitive performance and reduces tau pathology —

— Activation of a critical neuronal cell signaling pathway and microglia activation by CRT 001 correlates with improved cognitive performance —

NEW YORK, Nov. 12, 2014 (GLOBE NEWSWIRE) -- Cortice Biosciences announced today results from studies supporting the efficacy of preclinical drug candidates, TPI 287 and CRT 001, for the treatment of neurodegenerative diseases associated with cognitive impairment. Results will be presented in a poster session on Friday, November 14 at the Cell Symposia for Translational Neuroscience in Arlington, VA and on Wednesday, November 19 at the Society for Neuroscience in Washington, D.C.

TPI 287 is a brain penetrable microtubule stabilizing agent, which may be effective in treating diseases associated with microtubule destabilization, known as tauopathies. TPI 287 is currently in Phase 1 clinical development for the treatment of the rare tauopathies, progressive supranuclear palsy and corticobasal dementia, as well as Alzheimer's disease. CRT 001 is a small molecule partial agonist of the beta1 adrenergic receptor, which was previously on the market for the treatment of heart failure, and which has been shown to have profound activity in models of Alzheimer's disease and Down syndrome.

Presentations are as follows:

Title: Effects of TPI 287, a novel taxoid, on a transgenic mouse model of Alzheimer's disease
 
Date: Wednesday, November 19
Time: 1:00 - 5:00 PM ET
Place: 2014 Annual Meeting of the Society for Neuroscience
Poster #: 691.12/C48
Presenter: Erwin Defensor, Ph.D., Stanford Behavioral and Functional Neuroscience Lab

Preliminary results from on-going studies confirm that TPI 287 effectively penetrates the mouse blood-brain barrier, which correlates with cognitive function improvements in the PS19 tauopathy animal model. These effects were demonstrated by improved performance in the Morris water maze, a highly regarded behavioral test for measuring pharmacologic effects on learning and spatial working memory. Cognitive improvements were associated with a reduction of phosphorylated tau protein, which is the primary constituent of the hallmark neurofibliary tangles in the brains of tauopathy patients. Together, these results validate use of brain penetrable microtubule stabilizing agents such as TPI 287 for the treatment of tauopathies. Clinical evidence supporting this approach could come following analysis of on-going clinical trials once complete. 

Title: Targeting beta1-adrenergic pathway as a novel approach to treat Alzheimer's disease
 
Date: Friday, November 14
Time: 1:00 – 2:30 PM ET
Place: 2014 Cell Symposia for Translational Neuroscience
Poster: P2.59
Presenter: Mehrdad Shamloo, Ph.D., Stanford Behavioral and Functional Neuroscience Lab
 
Title: Role of beta1-adrenergic signaling in Alzheimer's disease (AD)
 
Date: Wednesday, November 19
Time: 8:00 AM - 12:00 PM ET
Place: 2014 Annual Meeting of the Society for Neuroscience
Poster #: 792.14/G4
Presenter: Mehrdad Shamloo, Ph.D., Stanford Behavioral and Functional Neuroscience Lab

Noradrenergic signaling has been shown to play a critical role in learning and memory formation in animals, and to be significantly impaired in patients with Alzheimer's and other neurodegenerative diseases. Stimulation of the beta1 adrenergic receptor with CRT 001 has previously been shown to improve cognitive function. Preliminary results from on-going studies presented in these two poster presentations demonstrate the unique ability of CRT 001 to specifically activate biochemical signaling pathways associated with long-term memory gene activation. Unlike other effectors of noradrenergic signaling, CRT 001 stimulates only this particular signaling pathway and not other signaling pathways associated with cardiovascular and pulmonary responses triggered by other beta adrenergic receptor agonists.  The results also show that CRT 001 can improve a variety of cognitive functions in Alzheimer's disease mice whether administered acutely (1 hour prior to behavioral testing) or chronically (2-3 months prior to and during behavioral testing). In addition, CRT 001 was shown to have potential disease modifying affects by stimulating the activity of immune cells specific to the central nervous system, known as microglia, along with a concomitant reduction of the aberrant Alzheimer's plaque peptide, Abeta1-40. These results further support the potential of CRT 001 as a treatment for diseases associated with cognitive impairment. Cortice intends to advance this agent into clinical trials in 2015. 

"Results from these studies demonstrate the potential of our CNS drug development pipeline," said George Farmer, Ph.D., Chief Executive Officer of Cortice. "The striking impact of a microtubule stabilizing agent like TPI 287 on both cognition and tau pathology supports the potential outcome of on-going Phase 1 tauopathy trials evaluating this drug candidate. Furthermore, the unique properties of CRT 001, combined with the excellent safety and tolerability profile already demonstrated in thousands of clinical subjects, support our view of the excellent potential of this drug for treating high unmet medical needs associated with cognitive impairment."     

About TPI 287

TPI 287 is a taxoid that binds to and stabilizes the assembly of microtubules similarly to the taxanes, paclitaxel and docetaxel. Compared with these other taxanes, TPI 287 has the distinct advantage of being able to readily penetrate the blood-brain barrier. Microtubule stabilization by TPI 287 in the brain may have potential as treatment of neurodegenerative diseases known as tauopathies that are associated with dysfunctional tau protein and defective microtubule architecture. Accordingly, TPI 287 is being developed for the treatment of the tauopathies progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and Alzheimer's disease (AD).  As an anti-cancer agent designed to inhibit cellular division and growth, TPI 287 is also being evaluated for the treatment of glioblastoma and secondary brain metastases.

About CRT 001

CRT 001 is a partial agonist of the beta1 adrenergic receptor, a family member of G-protein coupled receptors that control noradrenergic signaling, which are critical for learning and memory formation in mammals. Noradrenergic signaling is also significantly disrupted in diseases associated with dementia, including Alzheimer's disease.   CRT 001 was previously marketed in select European countries as xamoterol (Corwin) for the treatment of mild-to-moderate heart failure, and has been shown to be safe and well tolerated in over 70 published clinical trials that enrolled over 3,500 subjects. Based on this attractive clinical profile and highly compelling preclinical results, Cortice intends to develop CRT 001 for the treatment of diseases associated with cognitive impairment, which include Alzheimer's disease, Down syndrome, and several related orphan indications.    

About Cortice Biosciences

Cortice Biosciences, Inc. is a clinical-stage drug development company pioneering novel therapies for the treatment of oncologic and neurologic disease indications with urgent unmet medical need. More information can be found at www.corticebiosciences.com .

Safe Harbor Statement

This media release may contain forward-looking statements about Cortice Biosciences, which can be identified by the use of terminology such as "will," "would," "should," "expects," "anticipates," "intends," "plans," "believes," "may," "estimates," "predicts," "projects," or similar expressions intended to identify such statements.  These statements reflect the current views of Cortice with respect to future events, are based on assumptions, and subject to risks and uncertainties.

Cortice Biosciences, Inc. 646-747-9090

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Excel Treatment Center Adds ART Trauma Therapy Option

Updated Category News Views 101

Trauma rarely arrives at an addiction program wearing a name tag. Excel Treatment Center in Dover, New Jersey, is responding to that uncomfortable reality by adding Accelerated Resolution Therapy® (ART) to the individual, group, and family therapy already available to its clients. The center says its therapists have completed ART training, and the approach is now part of...

Continue Reading
Linkind's Best Buy Push Tests Smart Outdoor Demand

Updated Category News Views 160

Holiday lights have quietly become a year-round hardware category, and Linkind wants a louder seat at the table. The smart-lighting brand says three outdoor products have been in Best Buy stores across the United States since October 17, 2026: permanent exterior lights, decorative string lights, and solar pathway lights. That is a real distribution step, not some grand...

Continue Reading
Blue Diamond's $1 Billion Brand Meets Farm Realities

Updated Category News Views 56

A Ten-Cent Signal Carries Real Weight A ten-cent edge over the industry benchmark may not excite the cocktail-party crowd, but almond growers notice every penny when fertilizer, power and pest control keep gnawing at the farm gate. Blue Diamond Growers says it delivered payments roughly 10 cents above the benchmark in its latest year, alongside net profit that came in...

Continue Reading
Kendra Scott’s Dolly Tribute Tests Purposeful Luxury

Updated Category News Views 87

Butterflies, music notes, and a $70 pendant are carrying a surprisingly serious brand message this November. Kendra Scott’s new Dolly Parton Tribute Collection is plainly built to celebrate Dolly’s style, but it also shows how a consumer brand can make sentiment do some commercial heavy lifting without turning the whole thing into mush. The collection arrived November...

Continue Reading
Chaos Zero Nightmare's Award Is a Useful Signal for Games

Updated Category News Views 239

A story award can be easy to sneer at until a live-service game earns one across three markets. Smilegate's Chaos Zero Nightmare, a dark fantasy roguelike RPG developed by Super Creative, was named Best Story in Google Play's Best of 2026 awards for Taiwan, Hong Kong and Macau. That is not a sales figure, not a profit disclosure, and certainly not proof that a hit has...

Continue Reading
Vector Adds Mesa Division 10 Veteran for Arizona Growth

Updated Category News Views 61

A toilet-partition deal rarely raises eyebrows, but this one has the sturdy logic investors ought to notice. Vector Building Products has acquired Mesa-based Partitions & Accessories Co., a Division 10 specialist that has served Arizona contractors since 1978. It is not glamorous work. It is, however, the sort of necessary, specification-driven business that gets embedded...

Continue Reading
Chemours Legal Succession Gets a Long Transition Runway

Updated Category News Views 0

A corporate-law handoff rarely sets pulses racing, but this one deserves a proper look. Chemours is replacing its long-serving general counsel while keeping the departing executive in the building for four additional months. That is not flashy, and thank goodness for that. In a global chemicals company, legal leadership touches regulation, compliance, governance,...

Continue Reading
Villa Group’s Punta Mita Bet Adds 305 Luxury Resort Keys

Updated Category News Views 102

A 12.6-acre slice of Riviera Nayarit coastline is about to get a very expensive makeover, assuming The Villa Group can turn a handsome plan into a functioning resort without the usual development headaches. The company says it has acquired a beachfront parcel in Litibú and intends to build Villa La Valencia Punta Mita, a 305-accommodation luxury property aimed squarely...

Continue Reading
Premier Energy's €850M Debt Bet on Evryo Nears Close

Updated Category News Views 27

A Bridge Loan Gives Way to a Real Commitment Eight hundred and fifty million euros is not the sort of number a company tosses around for decoration. Premier Energy has secured a five-year senior facilities agreement to fund its planned acquisition of Evryo Group, including electricity distribution subsidiary Distribu?ie Energie Oltenia S.A., and to refinance roughly...

Continue Reading
Sokin’s UAE License Turns Expansion Into Real Payments Plumbing

Updated Category News Views 106

Dubai expansion headlines are cheap; regulated local money movement is not. That is why Sokin’s newly approved Dubai Financial Services Authority license deserves more than the usual fintech applause line. The company has paired that approval with AED accounts, local payment rails, a One Za’abeel office and a plan to double its UAE staff over the next year. None of...

Continue Reading

Top 5 Most Recently Viewed Articles

Latin Metals Gears Up for Drilling at Organullo Gold Project

Updated Category News Views 176

Latin Metals Achieves Drilling Milestone for Organullo Gold Project Latin Metals Inc. (TSXV: LMS) is excited to announce that it has successfully secured a crucial permit for exploration drilling at the Organullo Gold Project. This approval is a significant step forward in their commitment to mineral exploration in Argentina. What the Drill Permit Means for Latin Metals...

Continue Reading
TheSushiDragon Partners with StreamerDap to Empower Creators

Updated Category News Views 444

TheSushiDragon Joins StreamerDap as Co-Owner In a groundbreaking move for the live streaming community, TheSushiDragon, a prominent Twitch creator, has officially entered an equity partnership with StreamerDap, a leading platform revolutionizing the sponsorship landscape for creators. This innovative partnership aims to enhance the creator experience, making sponsorships...

Continue Reading
Tariffs, Inflation Insights: What Lies Ahead for Markets

Updated Category News Views 198

Market Trends: Understanding Recent Developments The market landscape has shown itself to be quite dynamic recently. As US President Donald Trump indicates the possibility of increased tariffs, there remains a juxtaposition of hope and uncertainty in the air. While discussions of a potential peace agreement between Russia and Ukraine seem to be gaining momentum, this has...

Continue Reading
Chaos Zero Nightmare's Award Is a Useful Signal for Games

Updated Category News Views 239

A story award can be easy to sneer at until a live-service game earns one across three markets. Smilegate's Chaos Zero Nightmare, a dark fantasy roguelike RPG developed by Super Creative, was named Best Story in Google Play's Best of 2026 awards for Taiwan, Hong Kong and Macau. That is not a sales figure, not a profit disclosure, and certainly not proof that a hit has...

Continue Reading
Bloom Energy Partners with Oracle to Boost AI Infrastructure

Updated Category News Views 301

Bloom Energy and Oracle: A Strategic Collaboration Bloom Energy Corp (NYSE: BE) is experiencing a notable surge in its stock prices following a recent announcement that highlights a significant partnership with Oracle Corp (NYSE: ORCL). This new collaboration aims to utilize Bloom's innovative fuel cell technology to deliver onsite power solutions for selected Oracle...

Continue Reading